Industry News
Sun in Canberra? Enough to make heat AND power!
The world's largest combined solar hot water and electricity system is coming to the Australian National University in Canberra.
[ + ]Big money for protein study
A protein involved in the detection of the most lethal form of DNA damage and which is also linked with a rare genetic disorder has attracted the largest single slice of the NHMRC's latest project funding round for Queensland. [ + ]
Chemeq moves into human pharma
Western Australian company Chemeq has signed an agreement with renowned University of Western Australia researcher Prof Barry Marshall to investigate the use of its CHEMEQ polymeric antimicrobial to treat ulcers caused by Helicobacter pylori. [ + ]
BresaGen to launch new manufacturing service
Adelaide's BresaGen Ltd is about to launch its new ProtEcol service to manufacture recombinant proteins and peptide therapeutics for client biotech companies in Australia and overseas. [ + ]
Opponent of ES cell research broadens attack
Embryonic stem cell research opponent Senator Ron Boswell has this week widened his criticism of the CEO-designate of the National Stem Cell Centre, Prof Alan Trounson, to include other high-profile members of the biotech community. [ + ]
Alchemia patents tipped to aid fundraising
Carbohydrate-based drug design and manufacture company Alchemia has secured two key patents on its technology platform that should aid its efforts to tie off a multimillion dollar fundraising exercise. [ + ]
New pact brings in funds for Ambri
Biosensor company Ambri will receive an injection of up to $15.7 million under an equity and technology licensing pact with Dow Corning Corp and diversified US biotech Genencor International. [ + ]
Qld biotech fund calls for proposals
The $100 million Queensland BioCapital Fund, whose formation was announced five months ago by the State government, is finally swinging its doors open for business. [ + ]
We're publishing (and perishing) as fast as we can
Fiddle with an old recipe and you may get an unpalatable, but not always unpredictable result. [ + ]
OGTR calls time out on GM crop applications
The Gene Technology Regulator, Dr Sue Meek, has decided to "stop the clock" on two applications for commercial release of genetically modified canola while she waits for updated information on technology stewardship, crop management strategies and supply chain management. [ + ]
Cancer treatment targeted by new QIMR agreement
Gene discovery and drug development company diaDexus has signed a deal with the Queensland Institute for Medical Research (QIMR) concerning a novel molecule with potential for treating cancers in both males and females. [ + ]
Transnational transgenic deal for CopyRat
Monash University spin-off CopyRat has entered into a joint venture with French company genOway to develop rat cloning technology. [ + ]
Eiffel unfazed by BattellePharma termination
The decision by the world's largest private biotech, BattellePharma, to terminate its research agreement with Melbourne-based drug re-engineering company Eiffel Technologies will have little effect on the company's financial position, an Eiffel spokesman said today. [ + ]
New receptor studies
What do certain anaesthetics, sedatives, and drugs for depression, anxiety and epilepsy have in common? [ + ]
Vision BioSystems: 'We've arrived'
Melbourne instrument manufacturer Vision BioSystems is claiming early international success for its new Bond immunochemistry and in situ hybridisation staining system. [ + ]
